These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 28844952)

  • 41. Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinoma.
    Zheng Y; Qin Y; Gong W; Li H; Li B; Wang Y; Chao B; Zhao S; Liu L; Yao S; Shi J; Shi X; Wang K; Xu S
    J Gastrointest Oncol; 2021 Dec; 12(6):2631-2642. PubMed ID: 35070393
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cholangiocarcinoma.
    Krasinskas AM
    Surg Pathol Clin; 2018 Jun; 11(2):403-429. PubMed ID: 29751883
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
    Montal R; Sia D; Montironi C; Leow WQ; Esteban-Fabró R; Pinyol R; Torres-Martin M; Bassaganyas L; Moeini A; Peix J; Cabellos L; Maeda M; Villacorta-Martin C; Tabrizian P; Rodriguez-Carunchio L; Castellano G; Sempoux C; Minguez B; Pawlik TM; Labgaa I; Roberts LR; Sole M; Fiel MI; Thung S; Fuster J; Roayaie S; Villanueva A; Schwartz M; Llovet JM
    J Hepatol; 2020 Aug; 73(2):315-327. PubMed ID: 32173382
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cholangiocarcinoma miscoding in hepatobiliary centres.
    Selvadurai S; Mann K; Mithra S; Bridgewater J; Malik H; Khan SA
    Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):635-639. PubMed ID: 33032867
    [TBL] [Abstract][Full Text] [Related]  

  • 45. On the role of IgG4 in inflammatory conditions: lessons for IgG4-related disease.
    Trampert DC; Hubers LM; van de Graaf SFJ; Beuers U
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1401-1409. PubMed ID: 28782655
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pathologic classification of cholangiocarcinoma: New concepts.
    Nakanuma Y; Kakuda Y
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):277-93. PubMed ID: 25966428
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Liver Transplantation for Intrahepatic Cholangiocarcinoma: Ready for Prime Time?
    Sapisochin G; Ivanics T; Heimbach J
    Hepatology; 2022 Feb; 75(2):455-472. PubMed ID: 34859465
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Drug-induced bile duct injury.
    Visentin M; Lenggenhager D; Gai Z; Kullak-Ublick GA
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1498-1506. PubMed ID: 28882625
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.
    Dong L; Lu D; Chen R; Lin Y; Zhu H; Zhang Z; Cai S; Cui P; Song G; Rao D; Yi X; Wu Y; Song N; Liu F; Zou Y; Zhang S; Zhang X; Wang X; Qiu S; Zhou J; Wang S; Zhang X; Shi Y; Figeys D; Ding L; Wang P; Zhang B; Rodriguez H; Gao Q; Gao D; Zhou H; Fan J
    Cancer Cell; 2022 Jan; 40(1):70-87.e15. PubMed ID: 34971568
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of CD15 expression in dysplastic and neoplastic tissue of the bile duct - a potential novel tool for differential diagnosis of indeterminate biliary stricture.
    Walter D; Herrmann E; Winkelmann R; Albert JG; Liese J; Schnitzbauer A; Zeuzem S; Hansmann ML; Peveling-Oberhag J; Hartmann S
    Histopathology; 2016 Dec; 69(6):962-970. PubMed ID: 27442966
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bile acid receptors in the biliary tree: TGR5 in physiology and disease.
    Deutschmann K; Reich M; Klindt C; Dröge C; Spomer L; Häussinger D; Keitel V
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1319-1325. PubMed ID: 28844960
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.
    Borad MJ; Gores GJ; Roberts LR
    Curr Opin Gastroenterol; 2015 May; 31(3):264-8. PubMed ID: 25763789
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neoadjuvant Chemotherapy for Intrahepatic, Perihilar, and Distal Cholangiocarcinoma: a National Population-Based Comparative Cohort Study.
    Parente A; Kamarajah SK; Baia M; Tirotta F; Manzia TM; Hilal MA; Pawlik TM; White SA; Dahdaleh FS
    J Gastrointest Surg; 2023 Apr; 27(4):741-749. PubMed ID: 36749556
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bile and urine peptide marker profiles: access keys to molecular pathways and biological processes in cholangiocarcinoma.
    Voigtländer T; Metzger J; Husi H; Kirstein MM; Pejchinovski M; Latosinska A; Frantzi M; Mullen W; Book T; Mischak H; Manns MP
    J Biomed Sci; 2020 Jan; 27(1):13. PubMed ID: 31900160
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Unveiling the immunogenomic landscape of cholangiocarcinoma: Identifying new prognostic markers and therapeutic targets based on CCL5 expression.
    Wang J; Xiang D; Dai Z; Zhu J; Du Y; Fu G; Chu X
    J Gene Med; 2024 Jan; 26(1):e3630. PubMed ID: 37985959
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
    Aitcheson G; Mahipal A; John BV
    Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
    [No Abstract]   [Full Text] [Related]  

  • 57. Different iron-handling in inflamed small and large cholangiocytes and in small and large-duct type intrahepatic cholangiocarcinoma.
    Mancinelli R; Cutone A; Rosa L; Lepanto MS; Onori P; Pannarale L; Franchitto A; Gaudio E; Valenti P
    Eur J Histochem; 2020 Oct; 64(4):. PubMed ID: 33131269
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy.
    Louis C; Edeline J; Coulouarn C
    Expert Opin Ther Targets; 2021 Feb; 25(2):153-162. PubMed ID: 33502260
    [No Abstract]   [Full Text] [Related]  

  • 59. KIF4A as a novel prognostic biomarker in cholangiocarcinoma.
    Zhang DY; Ma SS; Sun WL; Lv XCH; Lu Z
    Medicine (Baltimore); 2021 May; 100(21):e26130. PubMed ID: 34032761
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.